Stocks · News reference
Barclays analyst Glen Santangelo initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Overweight rating and announces Price Target of $345.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
On Thursday, Ligand Pharmaceuticals (NASDAQ:LGND) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call
HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $358 price target.